Reevaluation of Newborn Eye Infection Treatment by the USPSTF

Background on Newborn Eye Infections

Globally, a significant history of childhood blindness exists due to newborn pink eye or eye infections. These infections are typically caused by sexually transmitted diseases in mothers, resulting in symptoms such as red, goopy eyes. Notably, gonorrhea can lead to severe eye infections that may cause blindness, scarring, or perforation of the eye within 24 hours after birth.

US Preventive Services Task Force Review

The US Preventive Services Task Force (USPSTF) regularly reviews its clinical guidelines for treating patients who do not exhibit signs and symptoms of disease. Recently, the USPSTF revisited its 2011 recommendation that mandated all newborns receive eye medication to prevent gonorrhea-related eye infections.

Historical Context

In the late 19th century, approximately 10% of newborns in European hospitals were diagnosed with eye infections, leading to blindness in about 3% of cases. The causative agent was unidentified until 1879 when German physician Albert Neisser linked it to maternal gonorrhea. Following this discovery, Carl Credé introduced silver nitrate treatment in 1880, which was effective but caused significant eye irritation.

Current Preventive Measures

Today, most newborn eye infections are prevented in the United States through the administration of antibiotics to pregnant women with sexually transmitted diseases and to all newborns. Erythromycin is the sole FDA-approved medication for preventing gonorrhea-related eye infections in newborns. Standard practice involves applying erythromycin ointment to every newborn’s eyes immediately after birth.

Evidence Supporting Current Practices

The USPSTF’s decision to reevaluate its 2011 guidelines employed a rigorous process reserved for established standard-of-care practices, which requires substantial opposing evidence to alter recommendations. Reports from 2013 to 2017 indicated that fewer than one in 100,000 newborns in the US developed gonorrhea eye infections. Additionally, erythromycin ointment has been found to pose minimal risk to newborns, while untreated newborns face a 30% to 50% chance of contracting gonorrhea from their mothers.

USPSTF Conclusion and Future Research Needs

Based on the findings and lack of new contradictory evidence, the USPSTF reaffirmed its recommendation published in JAMA, stating that administering eye medication to all newborns effectively prevents gonorrhea-related infections. However, further research is essential to assess whether gonorrhea has developed resistance to erythromycin in the US, as antibiotic resistance has been reported in other countries, necessitating the exploration of alternative treatments.

International Perspectives on Newborn Treatment

The USPSTF’s approach to treat all newborns is supported by organizations such as the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, the Centers for Disease Control and Prevention, and the World Health Organization. In contrast, the Canadian Pediatric Society and several European nations advocate for screening and treating pregnant women for gonorrhea rather than medicating all newborns.

Conclusion

The USPSTF has confirmed its previous recommendation that administering eye medication to every newborn is crucial for preventing gonorrhea-related eye infections.

References

1. US Preventive Services Task Force. Ocular prophylaxis for gonococcal ophthalmia neonatorum: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019; 321(4):394–398. doi:10.1001/jama.2018.21367.
2. Centers for Disease Control and Prevention (CDC). 2015 sexually transmitted diseases treatment guidelines. CDC website. https://www.cdc.gov/std/tg2015/default.htm. Updated January 25, 2017. Accessed February 8, 2019.
3. Dekker R. The evidence on: erythromycin eye ointment for newborns. Evidence Based Birth Web site. https://evidencebasedbirth.com/is-erythromycin-eye-ointment-always-necessary-for-newborns/. Updated August 3, 2017. Accessed February 8, 2019.